Genolution

Genolution EBITDA per Employee

The EBITDA per Employee of Genolution (225220.KQ) as of Nov 11, 2026 is -99.33 M KRW. In the previous year, EBITDA per Employee was -92.20 M KRW — a change of 7.73% (lower).

EBITDA per Employee

-99.33 MKRW

YoY

7.73%

Last updated:

EBITDA per Employee of Genolution is 2025 -99.33 M KRW. EBITDA per Employee of Genolution was 2024 -92.20 M KRW. It decreases by 7.73% lower compared to the previous year.

The Genolution EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
4.64 M KRW
Jan 1, 2019
4.66 M KRW
Jan 1, 2020
625.65 M KRW
Jan 1, 2021
510.10 M KRW
Jan 1, 2022
182.62 M KRW
Jan 1, 2023
-81.27 M KRW
Jan 1, 2024
-92.20 M KRW
Jan 1, 2025
-99.33 M KRW
The Genolution EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-99.33 MKRW+7.73%
-92.20 MKRW+13.45%
-81.27 MKRW-144.50%
182.62 MKRW-64.20%
510.10 MKRW-18.47%
625.65 MKRW+13,339.03%
4.66 MKRW+0.35%
4.64 MKRW-45.69%
8.54 MKRW+382.74%
1.77 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

EBITDA per Employee of Genolution is -99.33 M KRW in 2025.

EBITDA per Employee of Genolution changed from -92.20 M KRW to -99.33 M KRW, representing a 7.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Genolution since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Genolution

All Key Metrics — Genolution